SCHEMBL10123196

SCHEMBL10123196

Cc1nc2c[n+]([O-])c3ccccc3c2n1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.39
LMNA P02545 3/20 0.39
ALDH1A1 P00352 1/20 0.39
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
RAB9A P51151 2/20 0.35
NPC1 O15118 1/20 0.35
HCRTR1 O43613 1/20 0.35
DPP4 P27487 1/20 0.35
MAPT P10636 4/20 0.34
GAA P10253 1/20 0.34
POLB P06746 2/20 0.33
TP53 P04637 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TLR7 Q9NYK1 1/20 0.33
PDE10A Q9Y233 1/20 0.33
TSHR P16473 2/20 0.32
AGER Q15109 1/20 0.32
CYP1A2 P05177 1/20 0.31
USP2 O75604 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2682175 0.86 MAPT (0.37) KDM4ELMNAALDH1A1MEN1KMT2A
SCHEMBL9211472 0.84 DHODH (0.43) KDM4EALDH1A1MEN1KMT2ARAB9A
SCHEMBL10728090 0.82 TSHR (0.41) KDM4ELMNAALDH1A1MEN1KMT2A
SCHEMBL10744471 0.82 MEN1 (0.35) KDM4ELMNAALDH1A1MEN1KMT2A
SCHEMBL10734771 0.80 MEN1 (0.36) KDM4ELMNAALDH1A1MEN1KMT2A
SCHEMBL10739285 0.79 TLR7 (0.50) LMNAALDH1A1MEN1KMT2ARAB9A
SCHEMBL4753949 0.79 NPC1 (0.34) LMNARAB9ANPC1MAPTGAA
SCHEMBL10734696 0.79 ALDH1A1 (0.40) KDM4ELMNAALDH1A1MEN1KMT2A
SCHEMBL10732400 0.78 PIK3CA (0.47) POLB
SCHEMBL10730689 0.78 MEN1 (0.55) KDM4ELMNAALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093390-B2 Substituted fused [1,2]imidazo[4,5-C] ring compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-01-10 US disclosed
US-20090005371-A1 Substituted Fused [1,2]Imidazo[4,5-C] Ring Compounds and Methods 3M INNOVATIVE PROPERTIES COMPANY 2009-01-01 US disclosed
US-4698348-A 1H-imidazo[4,5-c]quinolines and their use as bronchodilating agents RIKER LABORATORIES, INC. (US) 1987-10-06 US disclosed
US-4689338-A 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use RIKER LABORATORIES, INC. (US) 1987-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005371-A1 Substituted Fused [1,2]Imidazo[4,5-C] Ring Compounds and Methods IL2, IFNG, IL4 KDM4E 3148/4885LMNA 2548/4885ALDH1A1 890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.